全文获取类型
收费全文 | 151篇 |
免费 | 4篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 2篇 |
基础医学 | 7篇 |
口腔科学 | 2篇 |
临床医学 | 6篇 |
内科学 | 12篇 |
皮肤病学 | 1篇 |
神经病学 | 2篇 |
特种医学 | 9篇 |
外科学 | 45篇 |
预防医学 | 2篇 |
药学 | 4篇 |
肿瘤学 | 64篇 |
出版年
2022年 | 2篇 |
2021年 | 4篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 4篇 |
2014年 | 8篇 |
2013年 | 9篇 |
2012年 | 8篇 |
2011年 | 11篇 |
2010年 | 7篇 |
2009年 | 9篇 |
2008年 | 8篇 |
2007年 | 18篇 |
2006年 | 11篇 |
2005年 | 13篇 |
2004年 | 9篇 |
2003年 | 12篇 |
2002年 | 6篇 |
2001年 | 3篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1991年 | 1篇 |
1987年 | 1篇 |
排序方式: 共有157条查询结果,搜索用时 15 毫秒
1.
2.
Roberto Orecchia Umberto Veronesi Patrick Maisonneuve Viviana Enrica Galimberti Roberta Lazzari Paolo Veronesi Barbara Alicja Jereczek-Fossa Federica Cattani Claudia Sangalli Alberto Luini Pietro Caldarella Marco Venturino Daniele Sances Stefano Zurrida Giuseppe Viale Maria Cristina Leonardi Mattia Intra 《The lancet oncology》2021,22(5):597-608
3.
Torrisi R Colleoni M Veronesi P Rocca A Peruzzotti G Severi G Medici M Renne G Intra M Luini A Nolè F Viale G Goldhirsch A 《Breast (Edinburgh, Scotland)》2007,16(1):73-80
Patients with hormone receptor-positive tumors less often show a pathological complete response (pCR) than do those with hormone receptor-negative tumors. The addition of endocrine therapies may improve the clinical benefits of primary therapies in these patients. We investigated the efficacy of the epirubicin+cisplatin+fluorouracil (ECF) as continuous infusion) regimen in association with a gonadotropin-releasing hormone (GnRH) analog in 36 premenopausal women with T2-T4a-d N0-2 M0 ER and/or PgR-positive breast cancer. Median age was 39.5 years (range 26-53). Clinical response (complete or partial) was observed in 27 out of 36 patients (75% 95% CI 57.8-87.9%) and a pCR was observed in four patients (11%). Nine (25%) patients had stable disease and no progression was observed. Twenty-one patients (58%) were submitted for breast-conserving surgery and 15 had a radical mastectomy. No baseline clinical and biological characteristics significantly correlated with response. Thirty out of 31 patients evaluable for endocrine assessment had documented ovarian suppression, which occurred after a median of 28 days (range 20-43). We conclude that the combination of ECF and a GnRH analog is associated with a high response rate in the primary treatment of breast cancer. Further studies combining chemotherapy and endocrine agents are warranted in patients with hormone receptor-positive tumors. 相似文献
4.
Veronesi U Gatti G Luini A Intra M Orecchia R Borgen P Zelefsky M McCormick B Sacchini V 《The breast journal》2003,9(2):106-112
Interest in intraoperative radiation therapy (IORT) for breast cancer is increasing as the possible benefits of this technique for the patient become apparent. The rationale for the use of this segmental radiation therapy in place of whole-breast irradiation is based on the finding that approximately 85% of breast relapses are confined to the same quadrant of the breast as the primary tumor. Phase I and II trials have demonstrated no increase in postsurgical complication rates following the use of single-dose IORT in localized breast cancers. Longer follow-up is needed to assess the cosmetic outcome. Clinical trials to evaluate the effectiveness of IORT in the treatment of breast cancer are currently under way at the European Institute of Oncology (EIO) at the University of Milan, Italy, and at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York. Here we report the two different techniques in use in these trials. 相似文献
5.
Surgical technique of intraoperative radiotherapy in conservative treatment of limited-stage breast cancer 总被引:9,自引:0,他引:9
Intra M Gatti G Luini A Galimberti V Veronesi P Zurrida S Frasson A Ciocca M Orecchia R Veronesi U 《Archives of surgery (Chicago, Ill. : 1960)》2002,137(6):737-740
At the European Institute of Oncology, Milan, Italy, we have focused our interest on the use of intraoperative radiation therapy (IORT) in limited-stage breast cancer that is conservatively treated. A new technique to perform IORT was applied in 185 patients from July 1, 1999, to October 31, 2001. As the surgeon plays a crucial role in this procedure in selecting the patients, performing the breast resection, preparing the gland as a target to receive IORT, delivering the radiation directly to the mammary gland via a dedicated applicator, and, finally, reconstructing the breast, each phase of the surgical technique has been completely standardized and is described herein. The use of IORT in the conservative treatment of breast cancer could allow the course of external fractionated-dose radiation therapy to be completely avoided; IORT dramatically reduces radiation exposure of the skin, lung, and subcutaneous tissues and avoids the irradiation of the contralateral breast, which contributes to a very low incidence of radiation-induced sequelae. In our experience, IORT for limited-stage breast carcinoma is easy to perform and only briefly prolongs the duration of the surgical procedure. 相似文献
6.
Mario Ciocca Valeria Piazzi Roberta Lazzari Andrea Vavassori Alberto Luini Paolo Veronesi Viviana Galimberti Mattia Intra Andrea Guido Giampiero Tosi Umberto Veronesi Roberto Orecchia 《Radiotherapy and oncology》2006,78(2):213-216
PURPOSE: In a previous paper we reported the results of off-line in vivo measurements using radiochromic films in IOERT. In the present study, a further step was made, aiming at the improvement of the effectiveness of in vivo dosimetry, based on a real-time check of the dose. MATERIALS AND METHODS: Entrance dose was determined using micro-MOSFET detectors placed inside a thin, sterile, transparent catheter. The epoxy side of the detector was faced towards the beam to minimize the anisotropy. Each detector was plugged into a bias supply (standard sensitivity) and calibrated at 5 Gy using 6 MeV electrons produced by a conventional linac. Detectors were characterized in terms of linearity, precision and dose per pulse dependence. No energy and temperature dependence was found. The sensitivity change of detectors was about 1% per 20 Gy accumulated dose. Correction factors to convert surface to entrance dose were determined for each combination of energy and applicator. From November 2004 to May 2005, in vivo dosimetry was performed on 45 patients affected by early-stage breast cancer, who underwent IOERT to the tumour bed. IOERT was delivered using electrons (4-10 MeV) at high dose per pulse, produced by either a Novac7 or a Liac mobile linac. RESULTS: The mean ratio between measured and expected dose was 1.006+/-0.035 (1 SD), in the range 0.92-1.1. The procedure uncertainty was 3.6%. Micro-MOSFETs appeared suitable for in vivo dosimetry in IOERT, although some unfavourable aspects, like the limited lifetime and the anisotropy with no build-up, were found. Prospectively, a real-time action level (+/-6%) on dose discrepancy was defined. CONCLUSIONS: Excellent agreement between measured and expected doses was found. Real-time in vivo dosimetry appeared feasible, reliable and more effective than the method previously published. 相似文献
7.
Galimberti V Zurrida S Intra M Monti S Arnone P Pruneri G De Cicco C 《The breast journal》2000,6(5):306-309
From March 1996 to December 1999 we performed 1,266 sentinel node biopsies (SNBs) in patients with small breast cancers. The technique is to inject technetium 99m-labeled albumin particles close to the tumor, locate the sentinel node (SN) scintigraphically, and use a handheld gamma-detecting probe to guide its removal via a small incision during breast surgery. Our experience was divided into three phases. In the first phase, complete axillary dissection was performed to assess the accuracy of SNB in predicting axillary status. We also assessed safety, perfected tracer injection technique, determined optimal particle size and radioactivity levels, optimized lymphoscintigraphic scanning, and perfected the surgical technique. The SN was identified and removed in 98.7% of cases. Comparison with complete axillary dissection showed that the SN predicted axillary status in 96.8% of cases. However, use of an intraoperative frozen section method predicted axillary status in only 86.5% of cases. In the second phase we developed a new method for intraoperative histologic analysis. Extensive sampling (up to 60 sections/SN) and an experienced pathologist proved more important than use of antikeratin immunostaining in identifying tumor cells, and the new method has the accuracy of a definitive histologic examination. The third phase, a randomized trial, closed at the end of 1999. Trial objectives were to confirm that the SN predicts axillary status, to determine the number of axillary relapses, and to assess overall and disease-free survival. Patients were randomized in the operating room to complete axillary dissection or SNB. If the SN was positive, complete axillary dissection was performed; if the SN was negative, no further axillary treatment was given. We expect the trial to confirm our clinical experience that SNB is a safe and accurate procedure for staging patients with early breast cancer and a clinically negative axilla. 相似文献
8.
Intra M Trifirò G Viale G Rotmensz N Gentilini OD Soteldo J Galimberti V Veronesi P Luini A Paganelli G Veronesi U 《Annals of surgical oncology》2005,12(11):895-899
Background Sentinel lymph node biopsy (SLNB) is a safe and accurate axillary staging procedure for patients with primary operable breast
cancer. An increasing proportion of these patients undergo breast-conserving surgery, and 5% to 15% will develop local relapses
that necessitate reoperation. Although a previous SLNB is often considered a contraindication for a subsequent SLNB, few data
support this concern.
Methods Between January 2000 and June 2004, 79 patients who were previously treated at our institution with breast-conserving surgery
and who had a negative SLNB for early breast cancer developed, during follow-up, local recurrence that was amenable to reoperation.
Eighteen of these patients were offered a second SLNB because of a clinically negative axillary status an average of 26.1
months after the primary event.
Results In all 18 patients (7 with ductal carcinoma-in-situ and 11 with invasive recurrences), preoperative lymphoscintigraphy showed
an axillary sentinel lymph node, with a preoperative identification rate of 100%, and 1 or more SLNs (an average of 1.3 per
patient) were surgically removed. Sentinel lymph node metastases were detected in two patients with invasive recurrence, and
a complete axillary dissection followed. At a median follow up of 12.7 months, no axillary recurrences have occurred in patients
who did not undergo axillary dissection.
Conclusions Second SLNB after previous SLNB is technically feasible and likely effective in selected breast cancer patients. A larger
population and longer follow-up are necessary to confirm these preliminary data. 相似文献
9.
10.
Sentinel Lymph Node Metastasis in Microinvasive Breast Cancer 总被引:7,自引:3,他引:4
Intra M Zurrida S Maffini F Sonzogni A Trifirò G Gennari R Arnone P Bassani G Opazo A Paganelli G Viale G Veronesi U 《Annals of surgical oncology》2003,10(10):1160-1165
Background:Ductal carcinoma in situ with microinvasion (DCISM) is a separate pathological entity, distinct from pure ductal carcinoma in situ (DCIS). DCISM is a true invasive breast carcinoma with a well-known metastatic potential. Currently, there is controversy regarding the indication for complete axillary dissection (CAD) to stage the axilla in patients with DCISM. The role of CAD is questioned given its morbidity and reported low incidence of axillary involvement. Sentinel lymph node biopsy (SLNB) may obviate the need for CAD in these patients without compromising the staging of the axilla and the important prognostic information.Methods:From March 1996 to December 2002, 4602 consecutive patients with invasive breast carcinoma underwent SLN biopsy. Of these, 41 patients with DCISM were selected.Results:Metastasis in the SLN were detected in 4 of 41 (9.7%) patients. Two of the 4 patients had only micrometastasis in the SLN. In three patients, the SLN was the only positive node after CAD.Conclusions:SLN biopsy should be considered as a standard procedure in DCISM patients. SLNB can detect nodal micrometastasis and accurately stage the axilla avoiding the morbidity of a CAD. Complete AD may not be mandatory if only the SLN contains micrometastatic disease. Informed consent is very important in the decision not to undergo CAD. 相似文献